Thomas Wittmann1, Ulrike Schindlbeck1, Stefanie Höppner1, Susanna Kinting1, Sabrina Frixel1, Carolin Kröner1, Gerhard Liebisch2, Jan Hegermann3, Charalampos Aslanidis2, Frank Brasch4, Simone Reu5, Peter Lasch6, Ralf Zarbock1, Matthias Griese1. 1. Dr. von Hauner Children's Hospital, Ludwig-Maximilians University, German Centre for Lung Research, Munich, 80337, Germany. 2. Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Regensburg, Germany. 3. Institute of Functional and Applied Anatomy, Hannover Medical School, German Center for Lung Research (DZL), Hannover, Germany. 4. Department of Pathology, Academic Teaching Hospital Bielefeld, Bielefeld, Germany. 5. Department of Pathology, Ludwig-Maximilians University, Munich, Germany. 6. Pediatric Intensive Care, Hospital Bremen-Mitte, Bremen, Germany.
Abstract
BACKGROUND: Interstitial lung diseases (ILD) comprise disorders of mostly unknown cause. Among the few molecularly defined entities, mutations in the gene encoding the ATP-binding cassette (ABC), subfamily A, member 3 (ABCA3) lipid transporter represent the main cause of inherited surfactant dysfunction disorders, a subgroup of ILD. Whereas many cases are reported, specific methods to functionally define such mutations are rarely presented. MATERIALS AND METHODS: In this study, we exemplarily utilized a set of molecular tools to characterize the mutation K1388N, which had been identified in a patient suffering from ILD with lethal outcome. We also aimed to correlate in vitro and ex vivo findings. RESULTS: We found that presence of the K1388N mutation did not affect protein expression, but resulted in an altered protein processing and a functional impairment of ABCA3. This was demonstrated by decreased dipalmitoyl-phosphatidylcholine (PC 32:0) content and malformed lamellar bodies in cells transfected with the K1388N variant as compared to controls. CONCLUSIONS: Here we present a set of tools useful for categorizing different ABCA3 mutations according to their impact upon ABCA3 activity. Knowledge of the molecular defects and close correlation of in vitro and ex vivo data will allow us to define groups of mutations that can be targeted by small molecule correctors for restoring impaired ABCA3 transporter in the future. Pediatr Pulmonol. 2016;51:1284-1294.
BACKGROUND:Interstitial lung diseases (ILD) comprise disorders of mostly unknown cause. Among the few molecularly defined entities, mutations in the gene encoding the ATP-binding cassette (ABC), subfamily A, member 3 (ABCA3) lipid transporter represent the main cause of inherited surfactant dysfunction disorders, a subgroup of ILD. Whereas many cases are reported, specific methods to functionally define such mutations are rarely presented. MATERIALS AND METHODS: In this study, we exemplarily utilized a set of molecular tools to characterize the mutation K1388N, which had been identified in a patient suffering from ILD with lethal outcome. We also aimed to correlate in vitro and ex vivo findings. RESULTS: We found that presence of the K1388N mutation did not affect protein expression, but resulted in an altered protein processing and a functional impairment of ABCA3. This was demonstrated by decreased dipalmitoyl-phosphatidylcholine (PC 32:0) content and malformed lamellar bodies in cells transfected with the K1388N variant as compared to controls. CONCLUSIONS: Here we present a set of tools useful for categorizing different ABCA3 mutations according to their impact upon ABCA3 activity. Knowledge of the molecular defects and close correlation of in vitro and ex vivo data will allow us to define groups of mutations that can be targeted by small molecule correctors for restoring impaired ABCA3 transporter in the future. Pediatr Pulmonol. 2016;51:1284-1294.
Authors: June Y Hu; Ping Yang; Daniel J Wegner; Hillary B Heins; Cliff J Luke; Fuhai Li; Frances V White; Gary A Silverman; F Sessions Cole; Jennifer A Wambach Journal: Hum Mutat Date: 2020-04-01 Impact factor: 4.878
Authors: Jennifer A Wambach; Ping Yang; Daniel J Wegner; Hillary B Heins; Cliff Luke; Fuhai Li; Frances V White; F Sessions Cole Journal: Am J Respir Cell Mol Biol Date: 2020-10 Impact factor: 6.914
Authors: AlNashmi AlAnazi; Ralph Epaud; Humariya Heena; Alix de Becdelievre; Abeer Mohammad Miqdad; Pascale Fanen Journal: Ann Thorac Med Date: 2017 Jul-Sep Impact factor: 2.219
Authors: Kati J Dillard; Matthias Ochs; Julia E Niskanen; Meharji Arumilli; Jonas Donner; Kaisa Kyöstilä; Marjo K Hytönen; Marjukka Anttila; Hannes Lohi Journal: PLoS Genet Date: 2020-03-09 Impact factor: 5.917